Trevi Therapeutics (TRVI) Tops Q4 EPS by 1c

Trevi Therapeutics (NASDAQ: TRVI) reported Q4 EPS of ($0.11), $0.01 better than the analyst estimate of ($0.12).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• Worthington Industries (WOR) Misses Q4 EPS by 9c